INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $55,135,972 | +37.3% | 1,041,874 | +20.7% | 0.01% | +18.2% |
| Q3 2022 | $40,152,272 | -12.1% | 862,933 | +7.8% | 0.01% | -8.3% |
| Q2 2022 | $45,677,128 | +17.0% | 800,230 | +25.4% | 0.01% | +33.3% |
| Q1 2022 | $39,035,671 | +27.9% | 637,942 | +9.4% | 0.01% | +50.0% |
| Q4 2021 | $30,525,000 | +129.0% | 583,207 | +63.1% | 0.01% | +100.0% |
| Q3 2021 | $13,331,000 | -23.8% | 357,588 | -16.5% | 0.00% | -25.0% |
| Q2 2021 | $17,491,000 | +83.4% | 428,485 | +52.5% | 0.00% | +100.0% |
| Q1 2021 | $9,536,000 | -43.1% | 281,035 | -46.7% | 0.00% | -50.0% |
| Q4 2020 | $16,768,000 | +86.4% | 527,281 | +50.4% | 0.00% | +100.0% |
| Q3 2020 | $8,997,000 | -43.2% | 350,623 | -43.2% | 0.00% | -60.0% |
| Q2 2020 | $15,844,000 | +72.5% | 617,235 | +3.3% | 0.01% | +66.7% |
| Q1 2020 | $9,183,000 | +19.6% | 597,440 | +166.9% | 0.00% | +50.0% |
| Q4 2019 | $7,679,000 | +262.6% | 223,810 | -21.1% | 0.00% | +100.0% |
| Q3 2019 | $2,118,000 | -50.6% | 283,505 | -14.1% | 0.00% | 0.0% |
| Q2 2019 | $4,284,000 | +6.6% | 330,070 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $4,020,000 | +6.9% | 330,070 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $3,759,000 | -47.5% | 330,070 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $7,163,000 | +22.8% | 330,070 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $5,832,000 | -7.4% | 330,070 | +10.3% | 0.00% | 0.0% |
| Q1 2018 | $6,301,000 | +55.9% | 299,320 | +7.3% | 0.00% | +100.0% |
| Q4 2017 | $4,041,000 | -8.2% | 279,070 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $4,404,000 | +109.7% | 279,070 | +65.1% | 0.00% | +100.0% |
| Q2 2017 | $2,100,000 | -52.7% | 169,070 | -38.1% | 0.00% | -50.0% |
| Q1 2017 | $4,442,000 | +4.8% | 273,354 | -2.7% | 0.00% | 0.0% |
| Q4 2016 | $4,238,000 | +3.7% | 280,850 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $4,088,000 | -46.5% | 280,850 | +42.6% | 0.00% | -50.0% |
| Q2 2016 | $7,648,000 | – | 197,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |